Survey on the burden of sialorrhea symptoms in patients with parkinson's disease

Survey on the burden of sialorrhea symptoms in patients with parkinson's disease - Survey on the burden of sialorrhea symptoms in patients with parkinson's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060284

Enrollment

1400

Registered

2026-01-07

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients affiliated with PD patient organizations (specifically, the Kibou-no-kai for Young-Onset Parkinson's Disease and the Japan Parkinson's Disease Association) 2) Patients diagnosed with PD at least one month prior to the survey 3) Individuals aged 18 years or older, regardless of gender 4) Patients capable of self-completing the survey (assistance from a caregiver for input is permissible) 5) Patients able to provide voluntary informed consent for participation in this study

Exclusion criteria

Exclusion criteria: Patients currently participating in any interventional clinical trial

Design outcomes

Primary

Measure	Time frame
The total score and selection percentage for each symptom, based on a weighted ranking (1st rank = 5 points, 2nd = 4 points, 3rd = 3 points, 4th = 2 points, 5th = 1 point), derived from the top five most bothersome clinical symptoms (MS/NMS) experienced by Japanese PD patients in their daily life over the past month	—

Secondary

Measure	Time frame
-The total score and selection percentage for each symptom, based on a weighted ranking (1st rank = 5 points, 2nd = 4 points, 3rd = 3 points, 4th = 2 points, 5th = 1 point), derived from the top five most bothersome clinical symptoms (MS/NMS) experienced by Japanese PD patients in their daily life over the past month, within subgroups stratified by patient demographic and clinical characteristics -Patient demographic and clinical characteristics stratified by the specific symptom chosen as most bothersome -Results of supplementary questions regarding the impact of sialorrhea on QOL components (specific effects on constituents of QOL) targeting study participants who reported experiencing sialorrhea -Results of the supplementary questions regarding the impact on QOL within subgroups of participants who reported experiencing sialorrhea, specifically cohorts stratified by patient demographic and clinical characteristics, and those comparing patients who ranked sialorrhea among their top five most bothersome clinical symptoms versus those who did not	—

Measure

Time frame

-The total score and selection percentage for each symptom, based on a weighted ranking (1st rank = 5 points, 2nd = 4 points, 3rd = 3 points, 4th = 2 points, 5th = 1 point), derived from the top five most bothersome clinical symptoms (MS/NMS) experienced by Japanese PD patients in their daily life over the past month, within subgroups stratified by patient demographic and clinical characteristics -Patient demographic and clinical characteristics stratified by the specific symptom chosen as most bothersome -Results of supplementary questions regarding the impact of sialorrhea on QOL components (specific effects on constituents of QOL) targeting study participants who reported experiencing sialorrhea -Results of the supplementary questions regarding the impact on QOL within subgroups of participants who reported experiencing sialorrhea, specifically cohorts stratified by patient demographic and clinical characteristics, and those comparing patients who ranked sialorrhea among their top five most bothersome clinical symptoms versus those who did not

—

Countries

Japan

Contacts

Public ContactHonami Kawano

QLife Inc. Strategic Solution Planning & Development Dept

pd_drool@qlife.co.jp03-6860-5020

Outcome results